

ORGANISATION

Attendance Fee

950 € Regular

750 € Member of AGAH, EUFEMED

or Junior Scientist up to the age of 30

The participation fee is per person. Please note, according to §4 para 22 German turnover tax law, registration and workshop fees are exempt from VAT. Registration fees are charged and collected on behalf of AGAH e. V. All bookings are subject to change.

Registration Deadline: 27 September 2026

Registration Link

<https://forms.cloud.microsoft/e/haWzV7RgfP>

WORKSHOP VENUE

SocraTec R&D GmbH

Im Setzling 35

61440 Oberursel (Germany)

REGISTRATION

CSi Hamburg GmbH

Goernestraße 30

20249 Hamburg (Germany)

+49 40 30770 300

agah-meetings@csihamburg.de

CONTACT

Arbeitsgemeinschaft für angewandte

Humanpharmakologie (AGAH) e.V.

Office: Goernestraße 30

20249 Hamburg (Germany)

+49 40 30772097

info@agah.eu

www.agah.eu · www.studynurse.de

The content of this event is designed to be product- and service-neutral. We confirm that the scientific management and the speakers will disclose potential conflicts of interest to the participants. General pharmacokinetic principles are conveyed that do not relate to specific products or services. There is no sponsorship of the event, the total expenses of the event amount to approx. 10,000 € net and are financed by the participation fees.

Programme subject to modifications, status March 2026

CONTENT

Pharmacokinetics – prerequisite and at the same time “door opener” for understanding pharmacology!

This workshop, developed by experienced specialists from industry, CRO and consultancy, offers an entrée to physiological background, measures, and characteristics of pharmacokinetics. It helps to understand study design and evaluation of PK studies and the conclusions drawn from the results.

The workshop has been developed for clinical investigators, project leaders, project managers and monitors as well as PhD students in industry, hospitals, university and CROs. The knowledge obtained in this applied introductory course helps beginners in pharmacokinetics obtaining the basic knowledge and scientific background for professional handling, evaluation, and interpretation of PK data.

FACULTY

Dr. med. Ruwen Böhm (Course Director)

Medical Scientific Director

SocraTec R&D GmbH and Universitätsklinikum Schleswig-Holstein Erfurt (Germany)

Dr. Stephan Glund

Head of Clinical Pharmacology CREA

Boehringer Ingelheim Pharma GmbH & Co. KG
Biberach (Germany)

Dr. Roland Heinig

(formerly) Clinical Pharmacology

Bayer AG, Pharmaceuticals
Wuppertal (Germany)

Dr. med. vet. Joachim Höchel

Clinical Pharmacology

Bayer AG, Pharmaceuticals
Berlin (Germany)

Dr. Frank Runge

Clinical Pharmacology Lead

Boehringer Ingelheim Pharma GmbH & Co. KG
Biberach (Germany)

Helmut Schütz

BEBAC – Consultancy Services for Bioequivalence and

Bioavailability Studies

Vienna (Austria)

Dr. Ralph-Steven Wedemeyer

Advisor Biopharmaceutics; Head of Pharmaceutical Technology

SocraTec R&D GmbH
Oberursel (Germany)



AGAH

Arbeitsgemeinschaft
für angewandte
Humanpharmakologie e.V.

Association for Applied
Human Pharmacology



APPLIED COURSE

**INTRODUCTION INTO
BASIC PRINCIPLES
OF CLINICAL PHARMACOKINETICS**

**13-14 OCTOBER 2026
OBERURSEL (GERMANY)**

PROGRAMME · DAY 1 · 13 October 2026

- 08:00 Registration
- 08:30 **Welcome and introduction**
of participants and speakers
Ruwen Böhm, Joachim Höchel
- 08:40 **Introduction into basic terms and principles of Pharmacokinetics (PK)**
Joachim Höchel
- 09:30 **Human physiology: what you should know to better understand pharmacokinetics**
An overview of physiological characteristics being of (PK)-relevance for Absorption, Distribution, Metabolism and Elimination (ADME)
Roland Heinig
- 10:15 Break
- 10:30 **In vitro ADME & preclinical PK**
Description of in vitro ADME parameters, such as Cytochrome P450 & drug transporter inhibition, drug absorption, plasma protein binding, and metabolic clearance; explanation of preclinical animal PK results and their translation to the human situation
Frank Runge
- 11:15 **How to measure what happens in pharmacokinetics: PK metrics of relevance!**
An introduction into how one can quantify what the body does to the drug, i.e. which measures describe what happens to the drug including relevant methods of calculation
Helmut Schütz
- 12:00 Break

PROGRAMME · DAY 1 · 13 October 2026

- 13:00 **Human PK studies I: bioequivalence, food interaction and drug-drug-interaction studies**
Presentation of basic principles and design features such as choice of dosing, treatment and sampling schedule, evaluation approaches as well as population characteristics
Joachim Höchel
- 14:15 Break
- 14:30 **Human PK studies II: Special population characteristics considering kidney and liver impairment, age, sex, as well as genetic and ethnic factors**
Assessment of factors that relevantly impact PK in patients in adequately designed clinical trial considering authorities requirements
Roland Heinig
- 16:00 Break
- 16:15 **Hands-on clinical PK – the practical exercise:**
How to design your PK program? An exercise with the goal to plan your own clinical PK program based on a preclinical data set
All
- 17:30 **Discussion and Questions**
- 18:00 **End of Day 1 Workshop Program**
- 18:15 **Option of individual consultation of the speakers**
Participants are invited to consult individual speakers if they have specific questions/case studies they wish to discuss with an expert.

PROGRAMME · Day 2 · 14 October 2026

- 08:30 **Human PK – What's different in biologics?**
An introduction into types and molecular characteristics of biologics, bioanalytical methods, antibody development and their assessment, specificities in ADME, TMDD, immunogenicity, drug-drug interaction and comparability
Stephan Glund
- 10:15 Break
- 10:30 **Human PK studies III: interplay between biopharmaceutics and absorption**
What you should know about galenics and biopharmaceutics to understand the interplay between formulation principles and pharmacokinetics
Ralph-Steven Wedemeyer
- 11:30 **Discussion and Questions**
- 12:00 Break
- 13:00 **Human PK studies IV: Human drug metabolism**
How to determine the overall pathways of metabolism and excretion of an investigational drug and how to use these results in the context of drug safety (MIST, DDI).
Frank Runge
- 13:45 **Pitfalls in BA/BE**
Attempts in beating Murphy's law: Learnings from failures in study design, bioanalytics and statistics
Helmut Schütz
- 14:30 Break
- 14:45 **Where all ends meet**
- PK information in the label
Review of a PK program
– What, When, How – and Why?
All
- 16:00 **End of Workshop**